-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Yuandong Biology (688513.SH) announced that the first-class chemical innovation drug EP-0226 tablets jointly developed by the company, the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and the Zhongke Zhongshan Pharmaceutical Innovation Research Institute are undergoing a multi-center, randomized, double-blind, double-blind, double-simulation, placebo and pregabalin capsules in patients with post-herpes zoster neuralgia in China. Recently, the first case of patient administration was completed.
Share
Listen to the news
Zhitong Finance App News, Yuandong Biology (688513.SH) announced that the first-class chemical innovation drug EP-0226 tablets jointly developed by the company, the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and the Zhongke Zhongshan Pharmaceutical Innovation Research Institute are undergoing a multi-center, randomized, double-blind, double-blind, double-simulation, placebo and pregabalin capsules in patients with post-herpes zoster neuralgia in China. Recently, the first case of patient administration was completed.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending